{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T05:14:40Z","timestamp":1688793280869},"reference-count":6,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:p>Three new drugs are presented: dostarlimab, loncastuximab tesirine, and aducanumab. Product information, clinical trials, and recommendations are provided. Dostarlimab (Jemperli\u00ae) is FDA-indicated for the treatment of adult patients with mismatch repair deficient (dMMR - an abnormality\n that affects DNA repair) recurrent or advanced endometrial cancer (EC). Loncastuximab tesirine (Zynlonta\u00ae) is FDA-indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell\n lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. Aducanumab (Aduhelm\u00ae) is FDA-indicated for the treatment of Alzheimer\u2019s disease. It is an amyloid beta-directed antibody developed by Biogen of Cambridge, Massachusetts.\n This indication was approved on June 7, 2021, under the accelerated approval based on the reduction in amyloid beta plaques in patients treated with the drug.<\/jats:p>","DOI":"10.4140\/tcp.n.2022.9","type":"journal-article","created":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T04:32:31Z","timestamp":1640493151000},"page":"9-16","source":"Crossref","is-referenced-by-count":1,"title":["New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab"],"prefix":"10.4140","volume":"37","author":[{"given":"Lana","family":"Gettman","sequence":"first","affiliation":[{"name":"Harding University, Searcy, Arkansas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","volume-title":"Novel Drugs Approvals for 2021.","year":"2021"},{"key":"ref2","volume-title":"FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker.","year":"2021"},{"key":"ref3","year":"2021"},{"key":"ref4","volume-title":"FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma.","year":"2021"},{"key":"ref5","journal-title":"ADC Therapeutics\u2019 ZYNLONTA\u2122 (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network\u00ae Clinical Practice Guidelines in Oncology for B-cell Lymphomas."},{"key":"ref6","volume-title":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug.","year":"2021"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2022\/00000037\/00000001\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T04:50:18Z","timestamp":1642654218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2022.9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"alternative-id":["2639-9636(20220101)37:1L.9;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2022.9","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}